

ABSTRACT

5 The invention relates to stem cell compositions comprising anti-TGF- β treated stem cells which are viable for at least 14 days in culture without replication or differentiation and methods for rapid and long term *in vitro* hematopoiesis and *in vivo* hematopoietic reconstitution using such anti-TGF- β treated stem cells.